Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 19.71
(-0.05%)
CNY 19.71
(-0.05%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.32 Billion CNY | 110.28% |
| 2022 | 631.56 Million CNY | 28.11% |
| 2021 | 492.99 Million CNY | 40.14% |
| 2020 | 351.79 Million CNY | 36.06% |
| 2019 | 258.55 Million CNY | -32.47% |
| 2018 | 382.87 Million CNY | -28.25% |
| 2017 | 533.63 Million CNY | -11.02% |
| 2016 | 599.73 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.37 Billion CNY | 3.63% |
| 2024 Q3 | 1.49 Billion CNY | 20.18% |
| 2024 Q2 | 1.24 Billion CNY | -9.49% |
| 2023 Q3 | 1.33 Billion CNY | 69.12% |
| 2023 Q2 | 787.26 Million CNY | 21.62% |
| 2023 Q1 | 647.31 Million CNY | 2.49% |
| 2023 FY | 1.32 Billion CNY | 110.28% |
| 2023 Q4 | 1.32 Billion CNY | -0.25% |
| 2022 Q4 | 631.56 Million CNY | 21.46% |
| 2022 Q3 | 519.97 Million CNY | 8.5% |
| 2022 Q2 | 479.24 Million CNY | -2.46% |
| 2022 FY | 631.56 Million CNY | 28.11% |
| 2022 Q1 | 491.32 Million CNY | -0.34% |
| 2021 Q4 | 492.99 Million CNY | 2.61% |
| 2021 Q3 | 480.45 Million CNY | 6.02% |
| 2021 Q2 | 453.15 Million CNY | 17.72% |
| 2021 FY | 492.99 Million CNY | 40.14% |
| 2021 Q1 | 384.94 Million CNY | 9.42% |
| 2020 FY | 351.79 Million CNY | 36.06% |
| 2020 Q4 | 351.79 Million CNY | 23.87% |
| 2020 Q3 | 283.99 Million CNY | -1.56% |
| 2020 Q2 | 288.49 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q2 | 320.79 Million CNY | 0.0% |
| 2019 FY | 258.55 Million CNY | -32.47% |
| 2019 Q4 | 258.55 Million CNY | 0.0% |
| 2018 FY | 382.87 Million CNY | -28.25% |
| 2017 FY | 533.63 Million CNY | -11.02% |
| 2016 FY | 599.73 Million CNY | 0.0% |